

Unless otherwise defined herein, terms used in this announcement shall have the same meanings as those defined in the prospectus dated 24 October 2013 (the “Prospectus”) issued by China Pioneer Pharma Holdings Limited (the “Company”).

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Global Offering described below before deciding whether or not to invest in the Offer Shares.

This announcement (and the information contained herein) does not constitute, or form part of, an offer of securities for sale or a solicitation of an offer to buy securities of the Company in the United States or any other jurisdiction. The Offer Shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or the securities laws of any state of the United States or any jurisdiction other than Hong Kong, and may not be offered, sold, pledged or transferred within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act or any applicable state or local securities laws of the United States and outside the United States in accordance with Regulation S under the U.S. Securities Act. No public offering of the Shares will be made in the United States. This announcement (and the information contained herein) is not for release, publication or distribution, directly or indirectly, in or into the United States (including its territories and dependencies, any State of the United States and the District of Columbia).

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”) and Hong Kong Securities Clearing Company Limited (“HKSCC”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA PIONEER PHARMA HOLDINGS LIMITED

中国先锋医药控股有限公司

(incorporated in the Cayman Islands with limited liability)

GLOBAL OFFERING

Number of Offer Shares under the Global Offering	: 333,334,000 Shares (subject to adjustment and the Over-allotment Option)
Number of Hong Kong Offer Shares	: 33,334,000 Shares (subject to adjustment)
Number of International Offer Shares	: 300,000,000 Shares (subject to adjustment and the Over-allotment Option)
Maximum Offer Price	: HK\$5.00 per Share plus brokerage of 1.0%, SFC transaction levy of 0.003% and Hong Kong Stock Exchange trading fee of 0.005% (payable in full on application, subject to refund)
Nominal value	: US\$0.01 per Share
Stock code	: 01345

Sole Global Coordinator and Sole Sponsor



Joint Bookrunners and Joint Lead Managers



Application has been made by the Company to the Listing Committee of the Hong Kong Stock Exchange for the granting of the listing of, and permission to deal in, the Shares in issue and to be issued pursuant to the Global Offering and the Capitalisation Issue. The Global Offering comprises the Hong Kong Public Offering of initially 33,334,000 Shares, representing approximately 10% of the total number of Shares initially being offered in the Global Offering (subject to reallocation), and the International Offering of initially 300,000,000 Shares, representing approximately 90% of the total number of Shares initially being offered in the Global Offering (subject to reallocation and the Over-allotment Option). The allocation of the Offer Shares between the Hong Kong Public Offering and the International Offering is subject to reallocation as stated in “Structure of the Global Offering — The Hong Kong Public Offering” in the Prospectus.

Assuming the Hong Kong Public Offering becomes unconditional at or before 8:00 a.m. in Hong Kong on Tuesday, 5 November 2013, it is expected that dealings in the Shares on the Hong Kong Stock Exchange will commence at 9:00 a.m. on Tuesday, 5 November 2013. In the event that the Over-allotment Option is exercised, an announcement will be made on the website of the Company at www.pioneer-pharma.com and the website of the Hong Kong Stock Exchange at www.hkexnews.hk.

The Offer Price will not be more than HK\$5.00 per Share and is expected to be not less than HK\$4.10 per Share. Applicants for the Hong Kong Offer Shares are required to pay, on application, the maximum Offer Price of HK\$5.00 per Share together with a brokerage of 1.0%, SFC transaction levy of 0.003% and Hong Kong Stock Exchange trading fee of 0.005%, subject to refund should the Offer Price be lower than HK\$5.00.

Applications for the Hong Kong Offer Shares will only be considered on the basis of the terms and conditions of the Prospectus and the related Application Forms. Applicants who would like to be allocated the Hong Kong Offer Shares in their own names should complete and sign the **WHITE** Application Forms or submit applications online through the designated website of the **White Form eIPO** Service Provider www.eipo.com.hk under the **White Form eIPO** service. Applicants who would like to have the allocated Hong Kong Offer Shares issued in the name of HKSCC Nominees and deposited directly into CCASS for credit to their CCASS Investor Participant stock accounts or their designated CCASS Participants stock accounts should (i) complete and sign the **YELLOW** Application Forms which, together with copies of the Prospectus, may be obtained during normal business hours from 9:00 a.m. on Thursday, 24 October 2013 until 12:00 noon on Tuesday, 29 October 2013 at the Depository Counter of HKSCC at 2nd Floor, Infinitus Plaza, 199 Des Voeux Road Central, Hong Kong or their stockbrokers, who may have such Application Forms and Prospectus available; or (ii) give **electronic application instructions** to HKSCC via CCASS.

Copies of the Prospectus, together with the **WHITE** Application Forms, may be obtained during normal business hours from 9:00 a.m. on Thursday, 24 October 2013, until 12:00 noon on Tuesday, 29 October 2013 at:

UBS AG, Hong Kong Branch
52/F Two International Finance Centre
8 Finance Street
Central
Hong Kong

DBS Asia Capital Limited
17th Floor, The Center
99 Queen's Road Central
Hong Kong

Guotai Junan Securities (Hong Kong) Limited
27th Floor, Low Block
Grand Millennium Plaza
181 Queen's Road Central
Hong Kong

or any of the following branches of:

DBS Bank (Hong Kong) Limited

	Branch	Address
Hong Kong Island:	Head Office	G/F, The Center, 99 Queen's Road Central
	North Point Branch	G/F, 391 King's Road, North Point
Kowloon:	Tsimshatsui Branch	G/F, 22–24 Cameron Road, Tsimshatsui
	Hoi Yuen Road Branch	Unit 2, G/F, Hewlett Centre, 54 Hoi Yuen Road, Kwun Tong
New Territories:	Shatin Plaza Branch	Shops 47 & 48, Level 1, Shatin Plaza, No. 21–27 Sha Tin Centre Street, Shatin

The Bank of East Asia, Limited

	Branch	Address
Hong Kong Island:	Main Branch	10 Des Voeux Road Central, HK
	Wanchai Branch	Shop A–C, G/F, Easey Commercial Building, 253–261 Hennessy Road, Wanchai
Kowloon:	Mongkok Branch	638–640 Nathan Road
New Territories:	Metro City Plaza Branch	Shop 243, Level 2, Metro City Plaza I, Tseung Kwan O
	Ha Kwai Chung Branch	202 Hing Fong Road

Both **WHITE** and **YELLOW** Application Forms completed in all respects in accordance with the instructions printed thereon, to which cheques or banker's cashier orders payable to "**Ting Hong Nominees Limited — China Pioneer Pharma Public Offer**" should be securely stapled, should be deposited in the special collection boxes provided at any of the branches referred to above on the following dates during the following times:

Thursday, 24 October 2013 — 9:00 a.m. to 5:00 p.m.

Friday, 25 October 2013 — 9:00 a.m. to 5:00 p.m.

Saturday, 26 October 2013 — 9:00 a.m. to 1:00 p.m.

Monday, 28 October 2013 — 9:00 a.m. to 5:00 p.m.

Tuesday, 29 October 2013 — 9:00 a.m. to 12:00 noon

Applicants applying through **White Form eIPO** service may submit their applications through the designated website **www.eipo.com.hk** from 9:00 a.m. on Thursday, 24 October 2013 until 11:30 a.m. on Tuesday, 29 October 2013 (24 hours daily, except on the last application day) (or such later date as may apply in the case of a tropical cyclone warning signal number 8 or above or a "black" rainstorm warning signal being in force as described in "How to Apply for Hong Kong Offer Shares — 10. Effect of Bad Weather on the Opening of the Application Lists" in the Prospectus).

CCASS Participants can input **electronic application instructions** from 9:00 a.m. on Thursday, 24 October 2013 until 12:00 noon on Tuesday, 29 October 2013. The application lists will open from 11:45 a.m. to 12:00 noon on Tuesday, 29 October 2013 (or such later date as may apply in case of certain bad weather conditions as described in "How to Apply for Hong Kong Offer Shares — 10. Effect of Bad Weather on the Opening of the Application Lists" in the Prospectus). Please refer to "Structure of the Global Offering" and "How to Apply for Hong Kong Offer Shares" in the Prospectus for details of the conditions and procedures of the Hong Kong Public Offering.

The Company expects to publish the announcement on the Offer Price, the level of applications in the Hong Kong Public Offering, the level of indications of interest in the International Offering and the basis of allocation of the Hong Kong Offer Shares on Monday, 4 November 2013 in the South China Morning Post (in English) and the Hong Kong Economic Times (in Chinese), on the website of the Company at **www.pioneer-pharma.com** and the website of the Hong Kong Stock Exchange at **www.hkexnews.hk**.

Results of allocations of the Hong Kong Public Offering, the Hong Kong Identity Card/passport/Hong Kong business registration numbers of successful applicants (where appropriate) and the number of Hong Kong Offer Shares successfully applied for under **WHITE** and **YELLOW** Application Forms, through **White Form eIPO** service and by giving **electronic application instructions** to HKSCC via CCASS, will be made available through a variety of channels from Monday, 4 November 2013 as described in "How to Apply for Hong Kong Offer Shares — 11. Publication of Results" in the Prospectus.

The Company will not issue temporary documents of title or receipt for application monies paid. Share certificates will only become valid certificates of title provided that the Hong Kong Public Offering has become unconditional in all respects and the right of termination as described in the section entitled "Underwriting — The Hong Kong Public Offering — Hong Kong Underwriting Agreement — Grounds for termination" of the Prospectus has not been exercised, which is expected to be at 8:00 a.m. on Tuesday, 5 November 2013.

Dealings in the Offer Shares on the Hong Kong Stock Exchange are expected to commence at 9:00 a.m. on Tuesday, 5 November 2013. Our Shares will be traded in board lots of 1,000 Shares each. The stock code of our Shares is 01345.

By order of the Board
China Pioneer Pharma Holdings Limited
Li Xinzhou
Chairman

Hong Kong, 24 October 2013

As at the date of this announcement, the directors of the Company are Mr. LI Xinzhou and Mr. ZHU Mengjun as executive Directors, Mr. LU Yuan, Mr. WU Mijia and Mr. ZHANG Wenbin as non-executive Directors, and Mr. XU Zhonghai, Mr. LAI Chanshu and Mr. WONG Chi Hung, Stanley as independent non-executive Directors.

*Please also refer to the published version of this announcement in the **South China Morning Post** (in English) and the **Hong Kong Economic Times** (in Chinese).*